Literature DB >> 33464410

Nanobody: a promising toolkit for molecular imaging and disease therapy.

Guangfa Bao1, Ming Tang1, Jun Zhao2,3, Xiaohua Zhu4.   

Abstract

Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with many unique properties such as small size, excellent solubility, superior stability, quick clearance from blood, and deep tissue penetration. As a result, nanobodies have become a promising tool for the diagnosis and therapy of diseases. As imaging tracers, nanobodies allow an early acquisition of high-quality images, provide a comprehensive evaluation of the disease, and subsequently enable a personalized precision therapy. As therapeutic agents, nanobodies enable a targeted therapy by lesion-specific delivery of drugs and effector domains, thereby improving the specificity and efficacy of the therapy. Up to date, a wide variety of nanobodies have been developed for a broad range of molecular targets and have played a significant role in patients with a broad spectrum of diseases. In this review, we aim to outline the current state-of-the-art research on the nanobodies for medical applications and then discuss the challenges and strategies for their further clinical translation.

Entities:  

Keywords:  Cancer; Inflammation; Molecular imaging; Nanobody; Therapy

Year:  2021        PMID: 33464410     DOI: 10.1186/s13550-021-00750-5

Source DB:  PubMed          Journal:  EJNMMI Res        ISSN: 2191-219X            Impact factor:   3.138


  78 in total

Review 1.  Nanobodies as novel agents for cancer therapy.

Authors:  Hilde Revets; Patrick De Baetselier; Serge Muyldermans
Journal:  Expert Opin Biol Ther       Date:  2005-01       Impact factor: 4.388

2.  Ablynx makes nanobodies from llama bodies.

Authors:  Wendy Wolfson
Journal:  Chem Biol       Date:  2006-12

3.  Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.

Authors:  M Lauwereys; M Arbabi Ghahroudi; A Desmyter; J Kinne; W Hölzer; E De Genst; L Wyns; S Muyldermans
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

Review 4.  Immuno-imaging using nanobodies.

Authors:  Ilse Vaneycken; Matthias D'huyvetter; Sophie Hernot; Jens De Vos; Catarina Xavier; Nick Devoogdt; Vicky Caveliers; Tony Lahoutte
Journal:  Curr Opin Biotechnol       Date:  2011-07-02       Impact factor: 9.740

Review 5.  GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics.

Authors:  Azra Mujić-Delić; Raymond H de Wit; Folkert Verkaar; Martine J Smit
Journal:  Trends Pharmacol Sci       Date:  2014-03-30       Impact factor: 14.819

Review 6.  Exploiting Nanobodies' Singular Traits.

Authors:  Jessica R Ingram; Florian I Schmidt; Hidde L Ploegh
Journal:  Annu Rev Immunol       Date:  2018-02-28       Impact factor: 28.527

7.  Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains.

Authors:  S Muyldermans; T Atarhouch; J Saldanha; J A Barbosa; R Hamers
Journal:  Protein Eng       Date:  1994-09

8.  Naturally occurring antibodies devoid of light chains.

Authors:  C Hamers-Casterman; T Atarhouch; S Muyldermans; G Robinson; C Hamers; E B Songa; N Bendahman; R Hamers
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

Review 9.  The pharmacology and therapeutic applications of monoclonal antibodies.

Authors:  María Sofía Castelli; Paul McGonigle; Pamela J Hornby
Journal:  Pharmacol Res Perspect       Date:  2019-12

Review 10.  Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer.

Authors:  Isabel Van Audenhove; Jan Gettemans
Journal:  EBioMedicine       Date:  2016-04-30       Impact factor: 8.143

View more
  16 in total

1.  Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method.

Authors:  Yaqiu Wang; Nagakannan Pandian; Joo-Hui Han; Balamurugan Sundaram; SangJoon Lee; Rajendra Karki; Clifford S Guy; Thirumala-Devi Kanneganti
Journal:  Cell Mol Life Sci       Date:  2022-09-28       Impact factor: 9.207

Review 2.  Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections.

Authors:  Keke Huang; Tianlei Ying; Yanling Wu
Journal:  Viruses       Date:  2022-05-27       Impact factor: 5.818

Review 3.  A guide for single-particle chromatin tracking in live cell nuclei.

Authors:  Mengdi Zhang; Clayton Seitz; Garrick Chang; Fadil Iqbal; Hua Lin; Jing Liu
Journal:  Cell Biol Int       Date:  2022-01-30       Impact factor: 4.473

4.  Mapping paratopes of nanobodies using native mass spectrometry and ultraviolet photodissociation.

Authors:  Luis A Macias; Xun Wang; Bryan W Davies; Jennifer S Brodbelt
Journal:  Chem Sci       Date:  2022-05-16       Impact factor: 9.969

5.  A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach.

Authors:  Thomanai Lamtha; Sucheewin Krobthong; Yodying Yingchutrakul; Pawitrabhorn Samutrtai; Christopher Gerner; Lueacha Tabtimmai; Kiattawee Choowongkomon
Journal:  Proteome Sci       Date:  2022-05-16       Impact factor: 2.882

Review 6.  Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.

Authors:  Shuyang Sun; Ziqiang Ding; Xiaomei Yang; Xinyue Zhao; Minlong Zhao; Li Gao; Qu Chen; Shenxia Xie; Aiqun Liu; Shihua Yin; Zhiping Xu; Xiaoling Lu
Journal:  Int J Nanomedicine       Date:  2021-03-22

7.  Enzymatic ligation of an antibody and arginine 9 peptide for efficient and cell-specific siRNA delivery.

Authors:  Yu Ando; Hikaru Nakazawa; Daisuke Miura; Maho Otake; Mitsuo Umetsu
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

Review 8.  Nanobodies: new avenue to treat kidney disease.

Authors:  Nicola Wanner; Thomas Eden; Nastassia Liaukouskaya; Friedrich Koch-Nolte
Journal:  Cell Tissue Res       Date:  2021-06-16       Impact factor: 4.051

9.  Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate.

Authors:  Zhengyuan Zhou; Darryl McDougald; Rebecca Meshaw; Irina Balyasnikova; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Nucl Med Biol       Date:  2021-06-11       Impact factor: 2.947

10.  Llamanade : an open-source computational pipeline for robust nanobody humanization.

Authors:  Zhe Sang; Yufei Xiang; Ivet Bahar; Yi Shi
Journal:  bioRxiv       Date:  2021-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.